Key result
Although women exhibited higher on-treatment platelet reactivity than men, the incidence of the composite clinical endpoint at 1 year was similar between genders (6.8% vs 8.6%, OR 0.78).
Why the study?
Does female gender affect on-treatment platelet reactivity and clinical outcomes in patients on dual antiplatelet therapy undergoing elective coronary stent implantation compared to men?
Observational (n=951)
Does female gender affect on-treatment platelet reactivity and clinical outcomes in patients on dual antiplatelet therapy undergoing elective coronary stent implantation compared to men?
Effect estimate: OR 0.78 (95% CI 0.43-1.35)
Absolute Event Rate: 6.8% vs 8.6%
p-value: p=0.58
Although women on dual antiplatelet therapy exhibit slightly higher platelet reactivity than men, this difference does not translate into a higher incidence of adverse clinical outcomes after elective coronary stenting.
No takes yet. Share an insight, caveat, or question.
Similar outcomes despite higher reactivity in women on DAPT post-stenting; leaves open whether reactivity testing should guide gender-specific therapy.
Breet et al. (2011) conducted an observational in Coronary artery disease undergoing elective coronary stent implantation (n=951). Female gender vs. Male gender was evaluated on Composite of all-cause death, non-fatal myocardial infarction, definite stent thrombosis, and ischaemic stroke (OR 0.78, 95% CI 0.43-1.35, p=0.58). Although women exhibited higher on-treatment platelet reactivity than men, the incidence of the composite clinical endpoint at 1 year was similar between genders (6.8% vs 8.6%, OR 0.78).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: